CD276 and prostate carcinoma: As examples, XmAb808 may effectively combine with PSMA-, STEAP1-, or KLK2-targeted CD3 TCEs in prostate cancer; an ENPP3-targeted CD3 TCE in renal carcinoma; a CLDN6-targeted CD3 TCE in ovarian carcinoma; or a DLL3-targeted CD3 TCE in small cell lung cancer, as these tumor types express B7-H3 alongside these more specific tumor-associated antigens (11).